Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model

Anand, 2014, Therapeutics of Alzheimer's disease: past, present and future, Neuropharmacol, 76, 27, 10.1016/j.neuropharm.2013.07.004 Kumar, 2015, A review on Alzheimer's disease pathophysiology and its management: an update, Pharmacol Rep, 67, 195, 10.1016/j.pharep.2014.09.004 Prince, 2015 Stelzmann, 1995, An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde”, Clin Anat, 8, 429, 10.1002/ca.980080612 Karran, 2011, The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics, Nat Rev Drug Discov, 10, 698, 10.1038/nrd3505 Glenner, 1984, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun, 120, 885, 10.1016/S0006-291X(84)80190-4 Goldgaber, 1987, Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging, J Neural Transm Suppl, 24, 23 van der Kant, 2015, Cellular functions of the amyloid precursor protein from development to dementia, Dev Cell, 32, 502, 10.1016/j.devcel.2015.01.022 Muresan, 2015, Amyloid-β precursor protein: multiple fragments, numerous transport routes and mechanisms, Exp Cell Res, 334, 45, 10.1016/j.yexcr.2014.12.014 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Allaman, 2010, Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability, J Neurosci, 30, 3326, 10.1523/JNEUROSCI.5098-09.2010 Garcia-Matas, 2010, In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents, J Alzheimers Dis, 20, 229, 10.3233/JAD-2010-1365 Cizas, 2010, Size-dependent neurotoxicity of β-amyloid oligomers, Arch Biochem Biophys, 496, 84, 10.1016/j.abb.2010.02.001 Maezawa, 2011, Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity, J Biol Chem, 286, 3693, 10.1074/jbc.M110.135244 Pitschke, 1998, Detection of single amyloid [beta]-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy, Nat Med, 4, 832, 10.1038/nm0798-832 Mastrangelo, 2006, High-resolution atomic force microscopy of soluble Aβ42 oligomers, J Mol Biol, 358, 106, 10.1016/j.jmb.2006.01.042 Eckman, 2007, An update on the amyloid hypothesis, Neurol Clin, 25, 669, 10.1016/j.ncl.2007.03.007 Brambilla, 2011, Nanotechnologies for Alzheimer's disease: therapy, diagnosis and safety issues, Nanomedicine, 7, 521, 10.1016/j.nano.2011.03.008 Barone, 2014, Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets, Biochem Pharmacol, 88, 605, 10.1016/j.bcp.2013.10.030 Fernandez, 2013, Potential immunotargets for Alzheimer's disease treatment strategies, J Alzheimers Dis, 33, 297, 10.3233/JAD-2012-121222 Eskici, 2012, Copper and oxidative stress in the pathogenesis of Alzheimer's disease, Biochemistry, 51, 6289, 10.1021/bi3006169 Hellweg, 2012, Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD, Int J Geriatr Psychiatry, 27, 651, 10.1002/gps.2766 Hansen, 2008, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis, Clin Interv Aging, 3, 211 Querfurth, 2010, Alzheimer's disease, N Engl J Med, 362, 329, 10.1056/NEJMra0909142 Allgaier, 2014, An update on drug treatment options of Alzheimer's disease, Front Biosci, 19, 1345, 10.2741/4285 Toyn, 2015, What lessons can be learned from failed Alzheimer's disease trials?, Expert Rev Clin Pharm, 8, 267, 10.1586/17512433.2015.1034690 Sanhai, 2008, Seven challenges for nanomedicine, Nat Nanotechnol, 3, 242, 10.1038/nnano.2008.114 Farokhzad, 2009, Impact of nanotechnology on drug delivery, ACS Nano, 3, 16, 10.1021/nn900002m Re, 2011, Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide, J Biotechnol, 156, 341, 10.1016/j.jbiotec.2011.06.037 Balducci, 2014, Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models, J Neurosci, 34, 14022, 10.1523/JNEUROSCI.0284-14.2014 Song, 2014, Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta, ACS Nano, 8, 2345, 10.1021/nn4058215 Ordóñez-Gutiérrez, 2017, ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals, Biomaterials, 112, 141, 10.1016/j.biomaterials.2016.07.027 Fay, 2011, Antibody-targeted nanoparticles for cancer therapy, Immunotherapy, 3, 381, 10.2217/imt.11.5 Nicolas, 2013, Design and functionalization strategies for biodegradable/biocompatible polymer-based nanoparticles applied in targeted drug delivery, Chem Soc Rev, 42, 1147, 10.1039/C2CS35265F de Verdiere, 1997, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action, Br J Cancer, 76, 198, 10.1038/bjc.1997.362 Balland, 1994, The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with salmonella typhimurium, J Antimicrob Chemother, 33, 509, 10.1093/jac/33.3.509 Nicolas, 2009, Synthesis of poly(alkyl cyanoacrylate)-based colloidal nanomedicines, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 1, 111, 10.1002/wnan.15 Vauthier, 2003, Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications, Adv Drug Deliv Rev, 55, 519, 10.1016/S0169-409X(03)00041-3 Lenaerts, 1984, Degradation of poly(isobutyl cyanoacrylate) nanoparticles, Biomaterials, 5, 65, 10.1016/0142-9612(84)90002-4 Kattan, 1992, Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles, Invest New Drugs, 10, 191, 10.1007/BF00877245 Brambilla, 2012, PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease, ACS Nano, 6, 5897, 10.1021/nn300489k Le Droumaguet, 2012, Versatile and efficient targeting from a single nanoparticulate platform: application to cancer and Alzheimer's disease, ACS Nano, 6, 5866, 10.1021/nn3004372 Brambilla, 2010, Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging, Chem Commun, 46, 2602, 10.1039/b924028d Peracchia, 1999, Stealth (R) PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting, J Control Rel, 60, 121, 10.1016/S0168-3659(99)00063-2 Lazarov, 2005, Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice, Cell, 120, 701, 10.1016/j.cell.2005.01.015 Valero, 2011, Short-term environmental enrichment rescues adult neurogenesis and memory deficits in APP Sw, Ind transgenic mice, PLoS One, 6, 10.1371/journal.pone.0016832 Antunes, 2012, The novel object recognition memory: neurobiology, test procedure, and its modifications, Cogn Process, 13, 93, 10.1007/s10339-011-0430-z McDonald, 2012, The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain, Brain Res, 1450, 138, 10.1016/j.brainres.2012.02.041 Robb, 2015, High order W02-reactive stable oligomers of amyloid-beta are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-beta monomer, J Alzheimers Dis, 44, 69, 10.3233/JAD-132024 Yoo, 2010, Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects, Curr Pharm Des, 16, 2298, 10.2174/138161210791920496 Lundy, 2016, Distribution of systemically administered nanoparticles reveals a size-dependent effect immediately following cardiac ischaemia-reperfusion injury, Sci Rep, 6, 25613, 10.1038/srep25613 Kim, 2007, Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis, Biomacromolecules, 8, 793, 10.1021/bm060711a Kim, 2007, Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells, Cell Mol Life Sci, 64, 356, 10.1007/s00018-007-6390-x Gartziandia, 2016, Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease, J Biomed Nanotechnol, 12, 2220, 10.1166/jbn.2016.2313 Alexis, 2008, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol Pharm, 5, 505, 10.1021/mp800051m